Drug Interaction Report
1 potential interaction and/or warning found for the following 2 drugs:
- axicabtagene ciloleucel
- Buphenyl (sodium phenylbutyrate)
Interactions between your drugs
No drug ⬌ drug interactions were found between the drugs in your list. However, this does not necessarily mean no drug interactions exist. Always consult your healthcare provider.
Drug and food/lifestyle interactions
sodium phenylbutyrate food/lifestyle
Applies to: Buphenyl (sodium phenylbutyrate)
ADJUST DOSING INTERVAL: Coadministration with a high-fat meal may reduce the rate and extent of absorption of sodium phenylbutyrate. When a single 3 g-1 g dose of sodium phenylbutyrate-taurursodiol (sodium phenylbutyrate-ursodoxicoltaurine) was administered to healthy volunteers in the presence of a high-fat, high-calorie meal (approximately 800 to 1000 calories; 500 to 600 calories from fat, 250 calories from carbohydrate, 150 calories from protein), sodium phenylbutyrate peak plasma concentration (Cmax) decreased by 75% and systemic exposure (AUC) decreased by 55%. The Cmax for taurursodiol was not significantly affected, but AUC was increased by 46%. The clinical significance of these changes has not been established. In premarketing studies, patients were advised to take the drug before a meal.
MANAGEMENT: The prescribing information recommends administration of sodium phenylbutyrate-taurursodiol before a meal or snack, particularly in patients of low body weight (less than 70 kg).
References (2)
- (2022) "Product Information. Relyvrio (sodium phenylbutyrate-taurursodiol)." Amylyx Pharmaceuticals, 1
- (2022) "Product Information. Albrioza (sodium phenylbutyrate-ursodoxicoltaurine)." Innomar Strategies Inc.
Therapeutic duplication warnings
No duplication warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
See also:
Rituxan
Rituxan infusion is used to treat certain leukemias and lymphomas and some non-cancer conditions ...
Truxima
Truxima is used to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia, rheumatoid ...
Monjuvi
Monjuvi is used for relapsed or refractory diffuse large B-cell lymphoma (DLBCL) or follicular ...
Breyanzi
Breyanzi is a CAR T cell therapy for large B-cell lymphoma, CLL/SLL, follicular lymphoma, mantle ...
Kymriah
Kymriah is used to treat acute lymphoblastic leukemia (ALL) that is relapsing or refractory in ...
Polivy
Polivy (polatuzumab vedotin-piiq) is a targeted treatment that may be used to treat diffuse large ...
Yescarta
Yescarta is a CAR T-cell treatment used to treat relapsed or refractory large B-cell lymphoma ...
Xpovio
Xpovio is used to treat multiple myeloma (MM) or relapsed/refractory diffuse large B-cell lymphoma ...
Zynlonta
Zynlonta (loncastuximab tesirine) is used to treat relapsed or refractory diffuse large B-cell ...
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.